Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Process Updates
    • Human Clinical Trials
  • IsoPet®
    • IsoPet® Therapy
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • Our MIssion with IsoPet®
    • Animal Studies
      • Canine Studies
      • Feline Studies
  • About
    • Management & Consultants
    • Advisory Boards
  • Contact
  • Investors
    • Board of Directors
 (+1) 509‑736-4000,  
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Process Updates
    • Human Clinical Trials
  • IsoPet®
    • IsoPet® Therapy
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • Our MIssion with IsoPet®
    • Animal Studies
      • Canine Studies
      • Feline Studies
  • About
    • Management & Consultants
    • Advisory Boards
  • Contact
  • Investors
    • Board of Directors
  1. Investors

Investor Relations

Vivos, Inc.

Extending Life through Precision Radionuclide Therapy (PRnT)


OTCQB : RDGL

Vivos, Inc is a public company that trades on the OTC Markets under the symbol OTCQB: RDGL.

 

Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet®) and in humans (RadioGel™ ). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

 

RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.

 

The IsoPet® Solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.

 

In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet ® is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval is required. Following the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet ® to University animal hospitals and private veterinary clinics.

 

Mike Korenko
Vivos Inc. is a late stage development company engaged primarily in the development of brachytherapy devices for therapeutic applications. Vivos's focus is on transitioning to full operations upon receipt of expected FDA clearance for its patented brachytherapy cancer product, Yttrium-90 RadioGel™

( Michael Korenko, Sc.D. President & CEO )

INVESTOR CONTACT:

 


Vivos Inc.
Michael Korenko, Sc.D. – President & CEO

mkorenko@vivosinc.co

Safe Harbor Statement

 

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

IsoPet ® for treating animals uses the same technology as RadioGel ™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

Vivos Inc. (Trading symbol OTCQB:RDGL) is committed to providing shareholders with complete, up-to-the-minute information about the company. Our new website is under contruction. In the meantime on OTC Markets you'll find Press Releases, Financial Information, Board of Directors, Committee Composition, Governance Documents, and other corporate information.

 

Thank you for your past and continued support investing in Vivos Inc., and for supporting our mission of developing technologies that will improve human life.

Home Page Cover Image: 

 

Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

 

Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® Therapy Application(s)


Precision Radionuclide Therapy (PRnT)


Vivos Inc.
 - (OTCQB:RDGL) Investor Relations 

Contact

 

Main colors
   bg-primary
   bg-primary-light
   bg-primary-dark
   bg-secondary
   bg-secondary-dark
Template sections
   body
   top-header
   header
   content
Footer Styles
   background
   text color
   link color
   horizontal line
Buttons
   style 1
   style 2
   style 3
Other elements
  social icons
  navigation color
  subnav background
Mobile navigation
   background color
   navigation color
Template configurations
has-right-nav g-font
navigation styles
size-15 weight-400 snip-nav
content styles
form-white
footer styles
o-form color-white
Typography
Heading H1
weight-600
Heading H2
weight-600
Heading H3
weight-600
Buttons
weight-600 is-uppercase
Animations

Note:
All changes made here will be applied to your entire website.
is-switcher admin-only

draggable-logo

About | Privacy Policy | Cookie Policy | Sitemap
© 2022 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
Log out | Edit
  • Board of Directors
  • Scroll to top